Lung cancer is one of the most prevalent types of cancer in the world today. A new report reveals that contracting this sickness may become an early sign of the disease.
Express reports that bronchitis may become an early indicator of lung cancer. The signs and symptoms of lung cancer usually do not show up until the cancer itself has progressed, so spotting any subtle changes may be something to keep in mind. However, like with any other type of disease and not just cancer, many of the symptoms that are experienced may indicate other conditions, either serious or treatable.
Other symptoms of lung cancer include chest, back, or shoulder pains, persistent coughing, shortness of breath, coughing up blood, coughing up phlegm or mucus, loss of appetite, fatigue, muscle wasting, headaches, bone fractures, swelling in the face or in the neck, bleeding, blood clots, and some neurological symptoms like memory loss.
In case you or someone you know may be experiencing these symptoms, consult a doctor to get a proper diagnosis. They may prescribe the patient to undergo tests in order to determine the presence of cancer cells or not.
Although there is no exact cause for lung cancer, it is usually developed over time through many factors. Heavy smoking increases the risk, as well as constant exposure to cancerous substances like asbestos. Inhaling secondhand smoke also increases the risk of developing lung cancer, so it is best to keep away from smoking as well as steer clear of smoking areas. Exposure to pollution and previous respiratory diseases also increase the risk.
Meanwhile, as medical and technological advancements are made over recent years, sometimes there is a lot of red tape when introducing these advancements. A report by Bloomberg reveals that a drug for lung cancer called Tecentriq was rejected by the United Kingdom National Institute for Health and Care Excellence for not being cost-effective.
According to the organization, the average cost of lung cancer treatment with the drug would cost $43,100 alone. This is a high price to pay for patients, despite the drug’s ability to stimulate the body’s immune system to fight the cancer cells. It may be proven effective in extending survival in lung cancer patients by both the United States and European regulators, it is not economical enough.


FDA Adds Fatal Risk Warning to J&J and Legend Biotech’s Carvykti Cancer Therapy
U.S. Backs Bayer in Supreme Court Battle Over Roundup Cancer Lawsuits
U.S. Experts to Reassess Newborn Hepatitis B Vaccination Guidelines Amid Growing Debate
California Jury Awards $40 Million in Johnson & Johnson Talc Cancer Lawsuit
Eli Lilly Becomes First Pharma Giant to Hit $1 Trillion Amid Soaring Weight-Loss Drug Demand
Pfizer Secures $10 Billion Deal for Obesity Drug Developer Metsera, Outbids Novo Nordisk
Pfizer Sues Novo Nordisk Over Alleged Tactics to Block Obesity Drug Competition
Trump Signs Executive Order to Boost AI Research in Childhood Cancer
Pfizer Boosts Bid for Metsera Amid Intensifying Rivalry with Novo Nordisk in Obesity Drug Market
Merck Nears Acquisition of Cidara Therapeutics at Significant Premium
Eli Lilly’s Inluriyo Gains FDA Approval for Advanced Breast Cancer Treatment
U.S. Reveals 2026 Medicare Star Ratings: Aetna, UnitedHealth Lead in Quality Scores
Trump and Merck KGaA Partner to Slash IVF Drug Costs and Expand Fertility Coverage 



